Patents by Inventor Richard D. Cummings

Richard D. Cummings has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6177547
    Abstract: P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [3H]glucosamine-labeled HL-60 cell extracts on immobilized P-selectin. This molecule was characterized and distinguished from other well-characterized neutrophil membrane proteins with similar apparent molecular mass. The purified ligand, or fragments thereof (including both the carbohydrate and protein components), or antibodies to the ligand, or fragments thereof, can be used as inhibitors of binding of P-selectin to cells.
    Type: Grant
    Filed: December 8, 1998
    Date of Patent: January 23, 2001
    Assignee: The Board of Regents of the Unviersity of Oklahoma
    Inventors: Richard D. Cummings, Kevin L. Moore, Rodger P. McEver
  • Patent number: 6124267
    Abstract: Tyrosine sulfate on PSGL-1, particularly at least one of residues 46, 48 and 51, functions in conjunction with sialylated and fucosylated glycans, most preferably Thr-57, to mediate high affinity binding to P-selectin. PSGL-1 O-glycans have been determined to consist of disialylated or neutral forms of the core-2 tetrasaccharide Gal.beta.1.fwdarw.4GlcNAc.beta.1.fwdarw.6(Gal.beta.1.fwdarw.3)GalNAcOH. A minority of the O-glycans are .alpha.1,3 fucosylated that occur as two major species containing the sialyl Lewis x antigen--one species is a disialylated monofucosylated glycan:Fuc.alpha.1 .dwnarw. 3 NeuAc.alpha.2.fwdarw.3Gal.beta.1.fwdarw.4GlcNAc.beta.1 .dwnarw. 6 NeuAc.alpha.2.fwdarw.3Gal.beta.1.fwdarw.3GalNAc-R,and the other is a monosialylated, trifucosylated glycan having a polylactosamine backbone:Fuc.alpha.l .dwnarw. 3 NeuAc.alpha.2.fwdarw.3Gal.beta.1.fwdarw.4GlcNAc.beta.1.fwdarw.3Gal.beta.1. fwdarw. Fuc.alpha.l Fuc.alpha.l .dwnarw. .dwnarw. 3 3 4GlcNAc.beta.1.fwdarw.3Gal.beta.1.fwdarw.4GlcNAc.beta.1 .
    Type: Grant
    Filed: April 20, 1998
    Date of Patent: September 26, 2000
    Assignee: Southpac Trust Internationals, Inc.
    Inventors: Rodger P. McEver, Richard D. Cummings, Kevin L. Moore
  • Patent number: 6054315
    Abstract: Methods for treating and modulating an inflammatory response using compositions containing a primarily monomeric or primarily dimeric form of galectin-1. The dimeric form stimulates apoptosis of activated neutrophils while the monomeric form inhibits apoptosis of activated neutrophils. Methods of screening for compounds which have galectin-1-like functions are also identified.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: April 25, 2000
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Richard D. Cummings, Moon-Jae Cho
  • Patent number: 5948628
    Abstract: Methods for treating and modulating an inflammatory response using compositions containing a primarily monomeric or primarily dimeric form of galectin-1. The dimeric form stimulates apoptosis of activated neutrophils while the monomeric form inhibits apoptosis of activated neutrophils. Methods of screening for compounds which have galectin-1-like functions are also identified.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: September 7, 1999
    Assignee: The Board of Regents of The University of Oklahoma
    Inventors: Richard D. Cummings, Moon-Jae Cho
  • Patent number: 5880091
    Abstract: P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of ?.sup.3 H!glucosamine-labeled HL-60 cell extracts on immobilized P-selectin. This molecule was characterized and distinguished from other well-characterized neutrophil membrane proteins with similar apparent molecular mass. The purified ligand, or fragments thereof (including both the carbohydrate and protein components), or antibodies to the ligand, or fragments thereof, can be used as inhibitors of binding of P-selectin to cells.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 9, 1999
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Richard D. Cummings, Kevin L. Moore, Rodger P. McEver
  • Patent number: 5852175
    Abstract: P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of ?.sup.3 H!glucosamine-labeled HL-60 cell extracts on immobilized P-selectin. This molecule was characterized and distinguished from other well-characterized neutrophil membrane proteins with similar apparent molecular mass. The purified ligand, or fragments thereof (including both the carbohydrate and protein components), or antibodies to the ligand, or fragments thereof, can be used as inhibitors of binding of P-selectin to cells.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: December 22, 1998
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Richard D. Cummings, Kevin L. Moore, Rodger P. McEver
  • Patent number: 5576300
    Abstract: A method of preventing or treating infection by human rotavirus by administering an enteral nutritional product containing either bovine .kappa.-casein or human .kappa.-casein at a concentration greater than that found in human or bovine milk and sufficient to inhibit infection of mammalian cells by human rotavirus.
    Type: Grant
    Filed: September 16, 1994
    Date of Patent: November 19, 1996
    Assignee: Abbott Laboratories
    Inventors: Pradip Mukerji, Pedro A. Prieto, Amanda E.-Y. Seo, Jeffrey H. Baxter, Richard D. Cummings
  • Patent number: 5464778
    Abstract: P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [.sup.3 H]glucosamine-labeled HL-60 cell extracts on immobilized P-selectin. This molecule was characterized and distinguished from other well-characterized neutrophil membrane proteins with similar apparent molecular mass. The purified ligand, or fragments thereof (including both the carbohydrate and protein components), or antibodies to the ligand, or fragments thereof, can be used as inhibitors of binding of P-selectin to cells.
    Type: Grant
    Filed: July 21, 1994
    Date of Patent: November 7, 1995
    Assignee: Board of Regents of the University of Oklahoma
    Inventors: Richard D. Cummings, Kevin L. Moore, Rodger P. McEver
  • Patent number: 5125983
    Abstract: An extensive photovoltaic array for generating electric power from solar radiation as in a power plant includes an extensive unitary structural grid having substantial extent in both x and y directions and supported on a pedestal. The unitary structural grid is defined by a multiplicity of structural members connected to one another at angles and defining spaces therebetween. The structural grid has a depth sufficient to provide structural rigidity to the photovoltaic array. A large multiplicity of lens assemblies, each including at least one lens, is directly supported by and in spaces defined between structural members of the unitary structural grid. The lens assemblies close the upper side of the unitary structural grid. All other sides of the unitary structural grid are also closed. A plurality of solar cells are located within spaces defined between structural members of the structural grid and positioned to receive solar radiation that passes through respective lenses of the lens assemblies.
    Type: Grant
    Filed: April 22, 1991
    Date of Patent: June 30, 1992
    Assignee: Electric Power Research Institute, Inc.
    Inventor: Richard D. Cummings
  • Patent number: 4201188
    Abstract: A solar collector unit of triangular transverse cross section is provided with a corrugated heat trap element on at least the rear vertical wall of the collector. The heat trap element has a V-shaped cross section, the angle of the V being in the range of about 35.degree. to about 55.degree.. The heat trap element, in part, serves to increase the effective heat transfer surface of the collector at relatively little expense. Additionally, the corrugated member serves as a channel for direction of the flow of fluid to be heated through the collector.
    Type: Grant
    Filed: May 4, 1978
    Date of Patent: May 6, 1980
    Assignee: Exxon Research & Engineering Co.
    Inventor: Richard D. Cummings
  • Patent number: 4102325
    Abstract: Solar-to-thermal energy converter comprising an insulated frame, a solar energy absorber mounted in the frame, a fluid flow heat exchange means thermally coupled to the absorber to carry away as thermal energy the absorbed solar energy, and a window transmissive to solar energy mounted in the frame above the absorber, featuring a temperature actuated heat loss enhancer comprising a fluid flow heat pickup means thermally coupled to the absorber, an exterior heat rejector element, a fluid flow heat rejector means thermally coupled to the heat rejector element, and a thermally actuated valve connected between said fluid flow pickup and rejector means to form a fluid flow circuit separate from the fluid flow heat exchange means and powered by the heat-produced differential buoyancy forces of the fluid therein when the valve is open.
    Type: Grant
    Filed: May 4, 1977
    Date of Patent: July 25, 1978
    Assignee: Daystar Corporation
    Inventor: Richard D. Cummings